At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Financial Statements
- Click here to download Biogen Inc's Income Statement
- Click here to download Biogen Inc's Balance Sheet
- Click here to download Biogen Inc's Statement of Cash Flows
Key Info
- Industry: Biological Product (except Diagnostic) Manufacturing
- Sector: Manufacturing
- CEO Name: Michel Vounatsos
Key Statistics
- Stock Price: $290.9
- Dividend Yield: 0%
- Market Capitalization: $41,175,761,460
- Shares Outstanding: 144,001,404
- Number of Employees: 9,610
- Trailing 12-Month EPS: $19.55
- Trailing 12-Month DPS: $0
- Payout Ratio: 0.0%
Important Dates
- Next Earnings Date: 2023-02-15
- Next Ex-Dividend Date:
Price Trends
- Current Stock Price: $290.9
- 52-week high: $311.88
- 52-week low: $187.16
- 200-day moving average: $254.62
- 50-day moving average: $283.24
Performance
- 1-Month Price Return: 3.3%
- 3-Month Price Return: 0.6%
- 6-Month Price Return: 33.0%
- 1-Year Price Return: 27.0%
- 2-Year Price Return: 1.2%
- 5-Year Price Return: -18.9%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast